For the past two decades, Paul has established lasting relationships with key business leaders and stakeholders in Japan and the U.S., particularly in the Life Sciences field. He has completed transactions that influenced companies such as Celgene Corporation, Sumitomo Pharmaceuticals, Nobelpharma Co., Ltd, Teva Pharmaceuticals and Gilead.
Board of Directors
Curative Biotechnology, Inc.
Paul Michaels
Chairman of the Board of Directors and PresidentHe has also provided financial leadership and business development for almost 18 years to Inabata & Co. Ltd., one of Japan’s largest trading companies with $4.5 billion in annual sales. Throughout his tenure, he structured and closed major transactions that brought high-value products to the Japanese pharmaceutical market. Additionally, his other corporate responsibilities included overall evaluation of corporate asset values for purposes of divestiture or acquisition. Paul subsequently cofounded Nobelpharma, Ltd. Japan, an affiliate of Inabata & Co. Ltd., that is now one of Japan’s most successful orphan drug companies. As President of the U.S. division and a cofounder, he secured $35 million in initial capital and negotiated the license for the first designated orphan drug product in the company’s pipeline from Teva Pharmaceuticals.
As an adult-onset Type 1 diabetic, he knows firsthand how a patient can struggle to get the right diagnosis and treatment. Only 40,000 adults a year are diagnosed with Type 1 diabetes. Paul is actively involved in the Juvenile Diabetes Research Foundation (JDRF), an organization funding research for Type 1 diabetes.
Dr. Barry A. Ginsberg
Chief Strategy Officer and Vice ChairmanDr. Barry A. Ginsberg is an accomplished professional who advises executives across industries, bringing expertise in strategy and performance in the pharmaceuticals and medical-products sector. He also consults with healthcare companies to develop global strategies and operating models and is an experienced leader with a demonstrated history of success working as an entrepreneur in the health and wellness industry. He is skilled in comprehensive eye care which includes the diagnosis, treatment, management and prevention of diseases of the eye and visual system. Dr. Ginsberg has also participated in new Ophthalmic Drug and Procedure development trials utilizing his vast patient database.
Combined with an extensive network of contacts and an exclusive key opinion leader database throughout North America, Europe, Middle East, Asia, and South America, he brings consummate value to the team.
Dr. Ginsberg earned his Bachelor’s of Arts degree in Chemistry with a minor in Economics from Yeshiva University, and his Bachelor of Science and Doctorate degrees from the Pennsylvania College of Optometry. Concurrently, he attended the LaSalle College MBA Program in Philadelphia. He participated in four Externships including the Feinbloom Low Vision Center in Philadelphia, focusing on age-related macular degeneration (AMD) and the Goldschleger Eye Institute in Tel Hashomer Hospital in Israel, focusing on diseases of the eye including glaucoma.
Dr. Ginsberg’s community service participation included the Flying Samaritans and One Sight. He recently retired after practicing over 35 years in the medical field.
Cary Sucoff
Independent Director Chairman of the Audit CommitteeCary Sucoff is an accomplished executive with over 35 years of legal and securities industry experience, having participated in the financing of over one hundred public and private companies. His expertise in legal, compliance, corporate strategy, and capital markets benefits numerous healthcare and biotechnology companies where he serves as a director or advisor. Mr. Sucoff, a former New York City prosecutor, received a B.A. from SUNY Binghamton and a J.D. from New England School of Law where he was the Managing Editor of the Law Review and graduated Magna Cum Laude. Mr. Sucoff has been a member of the Bar of the State of New York (now retired) since 1978.
Lawrence S. Zaslow
Independent Director and Chairman of the Compensation CommitteeLarry Zaslow co-founded BioTheryX, Inc along with three Celgene scientists, including David Stirling, co-founder of Celgene. BioTheryX is a leader in protein degradation technology. In addition to being a founder, Mr. Zaslow also served as a director, president, and key executive over a period of fifteen years. During his tenure at BioTheryX Mr. Zaslow had primary responsibility for critical areas including strategic and operational planning, capital raising, financial planning/budget, corporate and business development, negotiation of licensing deals, investor and public relations. He helped position BioTheryX for its recent $100 million crossover round of financing and assembled a world class Scientific Advisory Board, including a Nobel Laureate. Mr. Zaslow was a founding managing director of Amphion PLC, engaged in the formation, financing, management and development of life science and technology companies seeking to commercialize their intellectual property. He earned his BA in Economics from Brandeis University, and his MBA in Finance from the Columbia Business School.
Michael K. Fish
DirectorMichael K. Fish received his Bachelors of Arts degree in accounting from Florida Atlantic University and is currently licensed as a CPA by the State of Florida. Mr. Fish founded a Certified Public Accounting firm in South Florida and possesses expertise in all areas of accounting, finance, and taxes for business including experience in the medical, wholesale, and professional services sectors.